Robert C. Flexon has served as the CEO of Dyne Therapeutics, Inc. since it emerged from bankruptcy in 2012. With a robust background in the energy sector, he oversaw the company’s shift towards a more sustainable business structure. Before joining...
Robert C. Flexon has served as the CEO of Dyne Therapeutics, Inc. since it emerged from bankruptcy in 2012. With a robust background in the energy sector, he oversaw the company’s shift towards a more sustainable business structure. Before joining Dynegy, he held notable positions at UGI Corporation and NRG Energy, gaining extensive experience in finance and operations. Flexon’s tenure is marked by strategic growth, and his leadership in transforming Dyne into a competitive player in the energy market is evident from his performance-driven compensation structure. In 2023, he earned a total compensation of $1,090,684, a combination of salary, bonuses, and other benefits reflecting the company's performance. Interestingly, Flexon has actively participated in buying Dyne’s stock, indicating confidence in the company’s future. His investments actually peaked around 2024, showcasing an upward trend in his stock ownership that aligns with the company’s recovery and growth over a decade. With a career spanning over many years in progressive roles, he combines strategic foresight with hands-on experience.